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Wei Zhu1†, Lai Wei2†, Hongwei Zhang1, Junxue Chen1 and Xinyu Qin1*Abstract
Background: Interleukin-24 (IL-24) is a cytokine that belongs to the IL-10 family. It can selectively induce cancer cell
apoptosis which has been utilized as a cancer gene therapy strategy.
Methods: A recombinant type five adenovirus containing IL-24 gene (designated CNHK600-IL24) was constructed,
whose replication is activated only in tumor cells. The replication of CNHK600-IL24 in breast tumor cells and
fibroblasts were assessed by TCID50 and MTT assay; the secretion of IL-24 was measured by ELISA and western
blotting. The in vivo anti-tumor effect of CNHK600-IL24 was investigated in nude mice carrying orthotopic or
metastatic breast tumor.
Results: We observed that CNHK600-IL24 could replicate efficiently and resulted in high level IL-24 expression and
massive cell death in human breast cancer cell MDA-MB-231 but not in normal fibroblast cell MRC-5. In addition,
orthotopic breast tumor growth in the nude mice model was significantly suppressed when CNHK600-IL24 was
administered. In the metastatic model generated by tail vein injection, CNHK600-IL24 virotherapy significantly
improved survival compared with the same virus expressing EGFP (median survival CNHK600-IL24, 55 days vs.
CNHK600-EGFP, 41 day, p < 0.05 Mantal-Cox test). A similar phenomenon was observed in the metastatic model
achieved by left ventricular injection as suggested by in vivo luminescence imaging of tumor growth.
Conclusion: The oncolytic adenovirus armed with IL-24, which exhibited enhanced anti-tumor activity and
improved survival, is a promising candidate for virotherapy of breast cancer.
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In women, breast cancer is the most frequently diag-
nosed malignant neoplasm and causes one of the highest
mortality among all malignancies. Worldwide, over 1.3
million new cases of invasive breast cancer are diag-
nosed, and more than 450,000 women die from breast
cancer annually [1]. Despite the advances made in the
diagnosis and treatment of early breast cancer which has
contributed to the declining mortality, metastatic breast
cancer remains an incurable disease. More efficacious
therapies to prevent relapse in early stage patients and
to treat metastatic disease are needed.
Interleukin-24 (IL-24) is an important immune medi-
ator, as well as a broad-spectrum tumor suppressor.* Correspondence: XYQin425@yahoo.cn
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reproduction in any medium, provided the orDelivery of IL-24 by liposome or adenovirus can specif-
ically inhibit growth of tumor cells and induce tumor-
specific apoptosis [2-6]. Traditional replication-defective
adenovirus cannot target tumor cells, which limits its
therapeutic value. Replication selective virotherapy
holds great promise for the treatment of cancer [7-9]
whose appealing features include tumor-selective target-
ing, viral self-spreading in cancer cells, and no cross-
resistance to current treatments. One strategy to
achieve tumor specificity is the use of tumor- or tissue-
specific promoters, such as MUC1, PSA, or PS2, to
drive adenoviral genes that are essential for replication
[10,11]. This system allows the oncolytic adenovirus to
selectively replicate in tumor cells without affecting
normal tissues [12]. Human telomerase reverse tran-
scriptase (hTERT) is a catalytic subunit of telomerase
and determines the activity of telomerase. The expres-
sion of hTERT is found in more than 85% of tumor. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Therapeutic genes under the control of the hTERT pro-
moter will selectively express in telomerase-positive tumor
cells at a high level [14]. In addition, in the progression of
malignancy, uncontrolled proliferation of tumor cells
often leads to a rapid increase in cellular oxygen con-
sumption, resulting in a hypoxic microenvironment within
the tumor, which is especially prominent in solid tumors.
Hypoxic signaling in tumor cells induces the expression of
hypoxia-inducible factor-1 (HIF-1) [15]. HIF-1 binds to
the hypoxia response element (HRE) and activates the
transcription of target genes. Therefore, the HRE pro-
moter can be introduced to recombinant adenovirus to
confine the oncolytic effect to hypoxic tumor cells. Com-
bining these specific promoters into dual-promoter con-
structs will further enhance the targeting of virus and
improve the safety of the treatment [16].
In this study, we used hTERT promoter to regulate the
adenoviral E1A gene, HRE promoter to control the
adenoviral E1B gene, and inserted the CMV promoter
driven IL-24 expression cassette between E1A and E1B
which resulted in the oncolytic adenovirus CNHK600-
IL24. We aimed to assess the antitumor selectivity and
therapeutic potential of CNHK600-IL24 for breast can-
cer both in vitro and in vivo.
Methods
Cells and cell culture
Human embryonic kidney 293 (HEK293) cells were pur-
chased from Microbix Biosystems. The human breast
cancer cell line MDA-MB-231 and the normal fibroblast
cell line MRC-5 were purchased from Shanghai Labora-
tory Animal Center, Chinese Academy of Sciences.
HEK293 and MRC-5 cells were maintained in Eagle’s
minimal essential medium (EMEM) supplemented with
10% fetal bovine serum (FBS), at 37°C, 5% CO2. MDA-
MB-231 cells were cultured in Leibovitz’s L15 medium
containing 10% FBS, at 37°C in CO2-free conditions.
Construction and preparation of the oncolytic adenovirus
CNHK600-IL24
The oncolytic adenovirus ZD55-IL24 was kindly provided
by Professor Xin-yuan Liu from the Shanghai Institutes
for Biological Sciences of the Chinese Academy of
Sciences. Plasmid pXC1 was purchased from Microbix
Biosystems Company, Canada. pClon9, pUC19-INS,
SG502-5CR2 and the adenovirus backbone plasmid pPE3
were constructed by the Laboratory of Gene and Viral
Therapy, Eastern Hepatobiliary Surgical Hospital, Second
Military Medical University, Shanghai. Restriction
enzymes were purchased from New England Biolabs.
Plasmid pCLON9 was digested with XhoI and SpeI,
and pUC19-INS was digested with XbaI and SalI. The
resulting 2680 bp and 1211 bp DNA fragments wereligated to create pCLON9-INS. The IL-24 expression
cassette includes the human cytomegalovirus (hCMV)
immediate-early promoter, the IL-24 gene and the SV40
PolyA sequence. It was extracted from ZD55-IL24 by
BglII digestion and inserted into pCLON9-INS, which
was digested with BamHI. The recombinant product
was named pCLON9-INS-IL24 and sent to Shanghai
GeneCore Biotechnologies Co. Ltd. for sequencing. After
digestion with AgeI and NotI, SG502-ΔCR2 and
pCLON9-INS-IL24 were ligated to form SG502-INS-
IL24. To obtain the virus, the plasmid SG502-INS-IL24
and type 5 adenovirus pPE3 were cotransfected into
HEK293 cells with Lipofectamine 2000 (GIBCO BRL).
The recombinant virus was verified by repeated PCR
amplification. The correct recombinant virus, named
CNHK600-IL24, was amplified in 293 cells and purified
by cesium chloride density gradient centrifugation.
Oncolytic adenovirus CNHK600-EGFP, which carries
enhanced green fluorescent protein (EGFP) as a reporter
gene, was constructed and prepared in the same way.
Median tissue culture infective dose method (TCID50)
was used to determine the virus titer.
Fluorescence microscopy
MDA-MB-231 cells and MRC-5 cells were infected with
CNHK600-EGFP at a multiplicity of infection (MOI) of
1 and observed under the fluorescence microscope.
Photographs were taken 48 h, 72 h and 96 h after
infection.
Viral replication assay
Logarithmic phase MDA-MB-231 and MRC-5 cells were
seeded at 1 × 105 cells/ml into 6-well plates. The cells
were infected with CNHK600-IL24 and CNHK600-
EGFP at MOI of 5. Two hours after incubation with the
viruses, the supernatants were discarded and replaced
with 3 ml culture medium containing 5% FBS. At time-
points 0, 12, 24, 48, 72 and 96 hours after infection, the
cells were scraped and transferred to five-ml centrifuge
tubes and underwent three cycles of freezing and thaw-
ing between 37°C and −80°C. The TCID50 method was
used to determine titre.
Cell growth inhibition assay
Log phase MDA-MB-231 cells and MRC-5 cells were
adjusted to 1 × 105 cells/ml with culture medium con-
taining 10% FBS, and 100 μl/well was added to 96-well
plates. The cells were incubated at 37°C for 18 h and
then infected with CNHK600-IL24 and CNHK600-EGFP
at MOI values of 0, 0.1, 0.5, 1, 5, 10, 100 and 1000. Two
hours after incubation with virus, the supernatants were
discarded and replaced with 100 μl culture medium con-
taining 5% FBS. Five days after infection, 100 μl 3-(4, 5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
Figure 1 The proliferation of oncolytic adenovirus expressive
EGFP. The MDA-MB-231 cells (A) and MRC-5 cells (B) were infected
with CNHK600-EGFP at a MOI of 1. The viral replication was
monitored under the fluorescence microscope at 48 hr (C, D), 72 hr
(E, F) and 96 hr (G, H) after infection.
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were incubated at 37°C for 4 h, and then the superna-
tants were discarded and 100 μl DMSO (Merker) was
added. After 15 min shaking, absorbances at 490 nm
were measured.
Detection of IL-24 protein in culture supernatants and
cells
Log phase MDA-MB-231 and MRC-5 cells were
adjusted to 1 × 105 cells/ml and added to 6-well plates.
The cells were infected with CNHK600-IL24 at a MOI
of 5. Two hours after incubation, the medium was
replaced with fresh culture medium supplemented with
5% FBS. Supernatants were collected at 12, 24, 48 and
96 h after infection. The expression of IL-24 was mea-
sured with a standard ELISA assay (GBD Biosciences
Catalog No. I083). At the same time, cells were lysed on
ice with 500 μl lysis buffer (10 mM Tris-Cl, pH 7.4,
0.15 M NaCl, 5 mM EDTA, 1% Triton X100, 5 mM
DTT, 0.1 mM PMSF, 5 mM E-aminocaproic acid) per
well. The cell lysates were centrifuged at 10,000 g, 4°C
for 10 min, and then the supernatants were stored at
−80°C until used for western blotting to detect the ex-
pression of IL-24 protein.
Establishment and treatment of the orthotopic breast
cancer model in nude mice
Nu/nu female mice, aged 5- to 6-weeks old and weigh-
ing about 18 to 20 g, were cultivated by the Shanghai
Experimental Animal Center of Chinese Academy of
Sciences. All procedures were approved by the Commit-
tee on the Use and Care on Animals and done in ac-
cordance with the institution guidelines. Log phase
MDA-MB-231-luc cells (Xenogen Corporation) were
diluted with sterile PBS to 8 × 107 cells/ml and mixed
with matrigel at a 1:1 ratio. After inhalation anesthesia,
50 μl cells were injected into the fat pad of nude mice.
At timepoints 14, 16, 18, 20 and 22 days after the injec-
tion of cells, viruses were administered through intra-
venous injection. Fifteen nude mice were divided into
groups as follows: each mouse in the control group was
injected with 100 μl saline, the CNHK600-EGFP group
was injected with 2 × 108 pfu virus (100 μl), the low-dose
group of CNHK600-IL24 received 1 × 108 pfu virus
(100 μl), the medium-dose group of CNHK600-IL24
received 2 × 108 pfu (100 μl), and the high-dose group of
CNHK600-IL24 received 4 × 108 pfu (100 μl). Biolumin-
escence was measured weekly using an in vivo imaging
system (IVIS 50, Xenogen Corporation). On day 42,
mice were sacrificed after anesthesia and the tumors
were separated, weighed and fixed in 4% formaldehyde.
The tumor inhibition rate was calculated according to
the following formula: Tumor Inhibition Rate = (mean of
tumor weight in control group - mean of tumor weightin treatment group)/mean of tumor weight in control
group × 100%.
Immunohistochemistry and in situ TUNNEL assay
Immunohistochemical analysis of hexon (GENWAYBIO)
and IL-24 (USCN LIFE, USA) was performed on paraffin
sections. Briefly, sections were deparaffinized in xylene,
hydrated through graded alcohols and water, endogen-
ous peroxidases were inactivated with 3% hydrogen per-
oxide in phosphate-buffered saline (PBS) followed by
incubation with the primary antibody for one hour at
room temperature and with the biotinylated secondary
antibody (anti-mouse IgG) for 1 hour. After incubation
with streatavidin-HRP for 10 minutes, sections were
washed and developed with DAB substrate for 3–10 min-
utes. For in situ TUNEL (Keygen Bio-Technology Devel-
opment Co., Ltd. Nanjing, China) assay, sections were
deparaffinized and hydrated as described above. After
proteinase K digestion, Terminal deoxynucleotidyl trans-
ferase (TdT) and dUTP-biotin was applied for 1hour at
37°C. After washing with PBS, sections were incubated
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10 min.
Establishment and treatment of metastatic model of
breast tumor
We used two models of metastatic breast cancer using
tail vein injection and left ventricular injection of
MDA-MB-231-luc cells. In the first model, MDA-MB-
231-luc cells was adjusted to 1 × 106 cells/ml, and
100 μl was intravenously injected into nude mice after
inhalation anesthesia. Viruses were intravenously admi-
nistrated on days 10, 12, 14, 16 and 18 after cell injec-
tion. Twenty-four nude mice were evenly divided into
three groups: each mouse in the control group was
injected with 150 μl saline, and each mouse in the
CNHK600-EGFP and CNHK600-IL24 groups received
4 × 108 pfu of the appropriate virus (150 μl). In vivo im-
aging of tumors was performed using IVIS 50 on day 0,
10, 17, 24, 31 and 38. The survival time of mice in each
group was recorded and plotted for survival curves. In
the second model, the same amount of MDA-MB-231-
luc cells were used and injected into the left heart ven-
tricle after inhalation anesthesia, followed by immediate
imaging to determine if the modeling was successful.Figure 2 CNHK600-IL24 selectively produced IL-24 and induced cell d
CNHK600-IL24 in MDA-MB-231 cells. MRC-5 or MDA-MB-231 cells were infe
supernatant were measured by the TCID50 method at indicated time poin
the indicated range of MOI, the viability of MDA-MB-231 and MRC-5 was mSix mice with successfully established metastases were
divided into two groups. The control mouse was
injected with 150 μl saline, and the mice in the
CNHK600-IL24 group were injected with 4 × 108pfu
(150 μl) of virus, administrated through the tail vein on
days 10, 12, 14, 16 and 18. In vivo imaging of tumors
was performed using IVIS 50 on days 0, 10, 17, 24, 31,
38 and 45. On day 45, mice were sacrificed after
anesthesia, and organs were separated, immersed imme-
diately in fluorescein (300 μg/ml) and tested for bio-
luminescence ex vivo.
Statistical analysis
The experimental data are presented as mean ± SD.
All statistical analyses were performed with the Statis-
tical Product and Service Solutions 12.0 (SPSS Inc.,
Chicago, USA) and Prism 5 (Praphpad, USA) software.
Student’s t-test and one-way ANOVA analyses were
employed to compare two groups and multiple groups
respectively. Survival curves were plotted according to
the Kaplan-Meier method and log-rank test was used
to compare survival of mice receiving different therap-
ies. Data were considered statistically significant when
p < 0.05.eath in a breast cancer cell line. (A) Selective replication of
cted with CNHK600-IL24 at a MOI of 5 and virus titers from the
ts. (B) Five days after infection with CNHK600-IL24 or CNHK600-EGFP at
easured by MTT assay.
Figure 3 Expression of IL-24 in MDA-MB-231cells and MRC-5
cells. (A) The concentration of IL-24 in the supernatant after
infection of CNHK600-IL24, as measured by ELISA. (B) Relative
quantification of IL-24 by western blotting, the expression of β-actin
was measured as loading control.
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Oncolytic activity of CNHK600-IL24 in vitro
We constructed the adenovirus containing IL-24 gene,
namely CNHK600-IL24, as described in the material and
method. The titer of CNHK600-IL24 after amplification
and purification was 1.9 × 1010 pfu/ml. The titer of
CNHK600-EGFP was 1.1 × 1010 pfu/ml. In order to test
the selective propagation of the recombinant virus, we
first observed the growth characteristics of the oncolytic
adenovirus expressing EGFP in malignant and normal
cells. After infection with CNHK600-EGFP, the expres-
sion of green fluorescence in MDA-MB-231 cells was
initially scattered and gradually turned into a wide-
spread, centralized and integrated presence, indicating
that the virus proliferated efficiently in breast cancer
cells. In contrast, only sparse fluorescence was observed
in normal fibroblast cells (MRC-5) after CNHK600-
EGFP infection, indicating no significant viral prolifera-
tion (Figure 1). The growth curve of CNHK600-IL24 in
MDA-MB-231 and MRC-5 cells were also measured. As
shown in Figure 2A, at 48 hours after infection, the pro-
liferation rate of CNHK600-IL24 in breast cancer cells
was significantly accelerated. The viral load was over
10,000 fold higher at 72 h, and 20,000 fold at 96 h post-
infection. In contrast, proliferation of the virus in MRC-
5 was not significant; the viral load was only 1000 fold
higher at 72 h and 96 h post-infection (Figure 2A). The
proliferation of CNHK600-EGFP in MDA-MB-231 and
MRC-5 was similar to that of CNHK600-IL24 (data not
shown).
Next, we assessed the selective killing of CNHK600-
IL24 on malignant tumor cells. As shown in Figure 2B,
at a MOI of 10, CNHK600-IL24 killed 57% of the breast
cancer MDA-MB-231 cells. At a MOI of 100, only 16%
of the cancer cells survived. In contrast, 94% of MRC-5
cells survived at a MOI of 100 of CNHK600-IL24. The
impact of CNHK600-EGFP on MDA-MB-231 cell sur-
vival was weaker than that of CNHK600-IL24, at the
same MOI of 100pfu/cell, 28.3% of the cancer cells sur-
vived after the infection of CNHK600-EGFP whereas
only 16.3% remained viable after CNHK600-IL24 infec-
tion (Figure 2B, p < 0.05 student’s t-test). This suggested
that expression of IL-24 enhanced the oncolytic activity
of adenovirus. The expression of IL-24 in breast cancer
cells and normal fibroblast was quantified by ELISA and
western blotting assays. As expected, 48 hours after in-
fection of CNHK600-IL24, the concentration of IL-24
protein in supernatants of infected breast cancer cells
was significantly elevated (3 ng/ml), whereas the level of
IL-24 MRC-5 cells remained low (Figure 3A). Similarly,
the expression of IL-24 protein in the lysates of breast
cancer cells was significantly increased, whereas the IL-
24 levels in normal fibroblasts remained difficult to de-
tect (Figure 3B).CNHK600-IL24 inhibited orthotopic breast tumor growth
and tumor metastasis in vivo
Having established the oncolytic property of CNHK600-
IL24 virus, we next investigated its anti-tumor activity in
mice models. We first established an orthotopic breast
tumor model in nude mice and the growth of tumor can
be visualized by live luminescence imaging. After injec-
tion of breast cancer cells, the tumors were detected
weekly with IVIS 50 (Figure 4A), and the photon counts
were measured. As illustrated in Figure 4B, the number
of photons in CNHK600-EGFP and CNHK600-IL24
groups were significantly lower than that of the control
group (one-way ANOVA, P < 0.05). Fourteen days after
injection, the tumors in all of the mice were palpable.
The growth curves of the tumors in each group are plot-
ted according to weekly measurements of tumor sizes
(Figure 4C). The tumor volumes of mice in the control
group were significantly greater than those of the
CNHK600-EGFP and CNHK600-IL24 groups (one-way
ANOVA, P <0.05).
Mice were sacrificed after anesthesia on day 42, and
the tumors were separated and weighed (Figure 4D). In
CNHK600-EGFP group, the tumor inhibition rate was
Figure 4 Suppression of the tumor in nude mice bearing orthotopic breast cancer after CNHK600-EGFP or CNHK600-IL24 was injected
by tail vein. Log phase MDA-MB-231-luc cells were injected into the fat pad of nude mice. At 14, 16, 18, 20 and 22 days after the injection of
cells, viruses were administered through intravenous injection at the dose of 2 × 108 pfu (CNHK600-EGFP and CNHK600-IL24 middle). The doses
for CNHK600-IL24 low and high group were 1× 108 and 4× 108 pfu respectively. Luminescent images were visualized every week (A), Photon
counts (B) and tumor volume (C) were also measured. Mice were sacrificed and tumor weight was measured on day 42 (D). Mouse serum was
collected on day 42 after orthotopic tumor cell inoculation. IL24 level was measured by ELISA (E) and serum ALT level was also quantified (F)
(N = 5 for each group).
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CNHK600-IL24 low-dose, medium-dose and high-dose
groups reached 36.91%, 42.98% and 49.86%, respectively
(P < 0.05, EGFP group vs. IL24 high-dose group student’s
t-test). In addition, we assessed the level of secreted IL24
in mouse serum. As shown in Figure 4E, injection of
CNHK600-IL24 in all three dosage schemes caused sig-
nificant elevation of serum IL24 compared with control
group(p < 0.05 in low dose, p < 0.01 in middle and high
dose) which was further confirmed by immunohisto-
chemical staining (see below). To examine potential
side-effects caused by adenovirus infection, we measured
serum ALT levels after treatment. A slight elevation in
ALT indicated that our tumor specific adenovirus did
not cause pronounced liver toxicity (Figure 4F). HE
staining revealed apparent tumor necrosis in CNHK600-
IL24 treatment group (Figure 5A, B). Immunohisto-
chemical assays showed that the expression of IL-24
protein and the adenovirus capsid protein hexon wereFigure 5 Histopathology and immunohistochemistry of tumor
tissues with CNHK600-IL24 treatment. HE staining of tumor tissue
in the control group (A) and in CNHK600-IL24 treatment group (B)
was visualized. The expression of adenovirus hexon protein (C, D)
and IL-24 (E, F) were monitored by immunohistochemistry. Breast
tumor cell apoptosis were measured by TUNEL assay (G, H).positive in the CNHK600-IL24 treatment group but
negative in the control group (Figure 5C, D, E, F).
TUNEL assay was utilized to measure apoptosis in
tumors. As shown in Figure 5G, 5H, the level of apop-
tosis in the CNHK600-IL24 treated tumors was signifi-
cant, whereas the level of apoptosis in the control group
was negligible.
We next examined whether CNHK600-IL24 can effect-
ively reduce breast tumor metastasis in a tail vein injection
model in nude mice. As shown in the Kaplan-Meier plot
(Figure 6A), the median survival in the control group was
30.5 days, whereas injection of the oncolytic adenovirus
significantly prolong the survival time (CNHK600-EGFP,
41 day, p < 0.05 and CNHK600-IL24, 55 days, p < 0.01,
Mantal-Cox test). When comparing CNHK600-EGFP
with CNHK600-IL24, a significant difference was also
observed (p= 0.0447, Mantal-Cox test). We further moni-
tored the growth of the metastatic tumor foci by in vivo
imaging (Figure 6B, 6C). Indeed, the ascending lumines-
cence signal as observed in the control mice was well sup-
pressed in the CNHK600-IL24 group.
We also assessed the anti-proliferative activity of
CNHK600-IL24 in a metastatic model by left ventricular
injection. Similarly, two of the three mice in control
group died on days 36 and 41, but the three CNHK600-
IL24-treated mice all survived more than 45 days. From
the 10th day on, all of the mice were tested using IVIS
50 every seven days. There was an obvious difference in
metastases between the control group and treatment
group (Figure 6D, 6E). On day 45, surviving mice were
sacrificed and the metastases were detected ex vivo.
There were extensive metastases in the only surviving
mouse of the control group. Tumors were visible in the
skull, mandible, scapula, clavicle, femur, brain, lung and
liver. In contrast, metastases in the treatment groups
were significantly reduced (data not show).
Discussion
Breast cancer is the most frequently diagnosed neoplasm
in women. Although great progress has been made in
treatment of breast cancer, very limited options are
available for metastatic breast cancer. Indeed, microme-
tastases within bone marrow or other tissues can lead to
relapse and metastasis and significantly accelerate the
progression of disease[17]. Targeted oncolytic adenovirus
brought new options for novel strategies to tackle these
difficult problems.
Compared with small molecule drug or recombinant
proteins, viruses have their unique properties, i.e.,
they can replicate and spread in addition to carrying
anti-tumoral therapeutic genes, and may be targeted
specifically to tumor cells. In recent years, the syner-
gistic anti-tumor effects of IL-24, including apoptosis-
inducing and immune-stimulating effects have gained
Figure 6 Inhibition of breast tumor metastasis by CNHK600-IL24. (A) Survival curves of mice in the metastatic model created by tail vein
injection of cancer cells. (N = 8 for each group) (B, C) In vivo imaging of the control and the CNHK600-IL24 group in the metastatic model
created by tail vein injection. (D, E) In vivo imaging of the control and CNHK600-IL24 group in the metastatic model generated by left ventricular
injection.
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transduction of IL-24 causes G2/M cell cycle arrest and
apoptotic cell death and this effect could be antagonized
by IL-10[18]. Patani et al. showed that recombinant IL-
24 reduced the motility and migration of MDA-MB-231
using wound healing and electric cell impedance sensing
assay. Furthermore, significantly lower expression of IL-
24 was also noted in tumors from patients who died of
breast cancer compared to those who remained disease
free. Low levels of MDA-7 were significantly correlated
with a shorter disease free survival[19]. Indeed, Introgentherapeutics has developed INGN241, a replication-
defective adenovirus carrying IL-24, which has shown
satisfactory efficacy and safety during phase I and phase
II clinical trials [20,21]. Sarkar et al. constructed Ad.
PEG-E1A-IL24 in which E1A was under the control of
PEG-3 promoter. In their study, breast cancer cell line
T47D cells were implanted subcutaneously in nude mice
to establish animal models, and the recombinant adeno-
virus was injected intratumorally. Four weeks after ad-
ministration, all tumors were eliminated, including the
contralateral abdominal metastases [22]. In theory, the
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targeting and thus is more suitable for clinical treatment
of cancer [23].
In this study, we constructed CNHK600-IL24, which
was regulated by both the hTERT and HRE promoters
and was armed with the IL-24 gene. Our replication se-
lective vector design is much more advantageous com-
pared with replication defective adenoviruses as previous
experience has indicated that the latter type cannot spe-
cifically target cancer cells. The EGFP gene was inserted
at the same position instead of IL-24 in CNHK600-
EGFP to facilitate the observation of virus proliferation
under the fluorescence microscope. Results showed that
CNHK600-EGFP replicated rapidly in tumor cells and
expressed the exogenous gene efficiently, which was fur-
ther verified by virus proliferation assay. In addition, in
vitro experiments confirmed that CNHK600-IL24 prolif-
erated specifically in breast cancer cells and selectively
killed tumor cells.
To evaluate the effects of CNHK600-IL24 in vivo, we
established an orthotopic breast cancer model by inject-
ing cells from the breast cancer cell line MDA-MB-231
harboring a luciferase gene (luc) into the mammary fat
pads of nude mice. Two metastatic models of breast
cancer were established by intravenous and left-
ventricular injection of tumor cells. An in vivo optical
imaging system was applied to observe the inhibitory ef-
fect of the CNHK600-IL24 adenovirus on breast cancer
in vivo. In vivo optical imaging technology allows con-
tinuous observation of the same group of animals, which
results in more significant and reliable data [24].
In the orthotopic breast cancer model in nude mice, the
results of in vivo imaging showed that the number of
photons in the CNHK600-EGFP group and the
CNHK600-IL24 treatment group were significantly lower
than those of the control group. The tumor volumes of
the CNHK600-EGFP group and the CNHK600-IL24 treat-
ment group were also significantly smaller, demonstrating
the potent anti-tumor effects of the oncolytic adenovirus
CNHK600-IL24. Large areas of necrosis in tumor tissue
were found by pathological assay, which possibly resulted
from continuous replication of the oncolytic adenovirus
and the ultimate lysis of tumor cells. Immunohistochem-
ical analysis showed that in the CNHK600-IL24 treatment
group, tumor cells were strongly positive for the adeno-
viral capsid protein hexon, whereas those of the control
group were negative. This illustrates that after injection of
CNHK600-IL24 through the tail vein, the virus reached
the tumor and effectively replicated in the tumor cells.
In the metastatic model by tail vein injection, there was
intense luminescence in the lungs of the control mice, but
the photon intensity in the CNHK600-IL24 treated mice
was significantly weakened. The survival time of mice in
control group was significantly shorter than that of theCNHK600-EGFP and CNHK600-IL24 groups. Further-
more, tumor-bearing mice in CNHK600-IL24 group sur-
vived longer than those of the CNHK600-EGFP group,
indicating that the gene-virotherapy was more effective
than virotherapy alone. Similarly, in the metastatic model
by left ventricular injection, the intensity of fluorescence
in treatment groups was significantly weaker than that of
the control group. In addition, ex vivo imaging showed
reduced metastases in CNHK600-IL24 treated mice.
Conclusions
Our in vitro and in vivo observations demonstrated that
oncolytic adenovirus expressing IL-24 can actively des-
troy breast tumor and significantly prolong survival. We
hope that this targeting gene-virotherapy will provide a
promising strategy for breast cancer treatment in com-
bination with chemotherapy or other therapeutic modal-
ities in the future.
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